Cargando…
Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea
BACKGROUND: Global assessment allows patients to assess improvement in multiple irritable bowel syndrome (IBS) symptoms. However, it was deemed important to assess “clinically meaningful improvements, focusing on the patient’s chief complaint and the severity of major IBS symptoms” in addition to gl...
Autores principales: | Ida, Motoko, Nishida, Akito, Akiho, Hiraku, Nakashima, Yoshihiro, Matsueda, Kei, Fukudo, Shin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356323/ https://www.ncbi.nlm.nih.gov/pubmed/28331539 http://dx.doi.org/10.1186/s13030-017-0093-9 |
Ejemplares similares
-
Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017) -
Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
por: Chiba, Toshimi, et al.
Publicado: (2013) -
Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey
por: Kosako, Masanori, et al.
Publicado: (2018) -
Efficacy of Ramosetron in Male Patients With Irritable Bowel Syndrome With Diarrhea (Neurogastroenterol Motil 2011;23:1098-1104)
por: Cha, Bong Ki, et al.
Publicado: (2012) -
Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials
por: Qi, Qingqing, et al.
Publicado: (2018)